Taiwan’s establishment of a well-formulated Patent Linkage system for pharmaceuticals is a landmark development not only for the drug industry but for this country’s intellectual property rights protection in general. In addition, it boosts Taiwan’s status in the global trading community and improves its prospects for eventually concluding bilateral or multilateral free trade agreements with…

The Taiwan government deserves congratulations for its recent enactment of landmark legislation establishing a Patent Linkage system for pharmaceutical products, a mechanism designed to prevent infringing drugs from being licensed while an original medication still holds a valid patent in this market. Credit goes both to the executive branch agencies that ushered through this initiative…

“Robust intellectual property (IP) protection is vital for biopharmaceutical innovation,” stresses a recently released report from Geneva Network, a UK-based public policy research and advocacy organization specializing in international intellectual property, health, and trade issues. The report – written by Geneva Network researcher Jack Ellis, a former Asia-Pacific editor of Intellectual Asset Management magazine –…

A visiting delegation urges early passage of Patent Linkage legislation. During a recent visit to Taipei, a six-member delegation from the Washington, DC-based Pharmaceutical Research and Manufacturers of America (PhRMA) urged Taiwan’s legislature to give early attention to pending bills to strengthen intellectual property protection for pharmaceuticals. Passage of the proposed amendments to the Pharmaceutical…